Asset
COSIBELIMAB
TG THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03778073 | phase1 | terminated | 2019-04-17 | 2022-05-03 | TG Therapeutics, Inc. | Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma |
| NCT02535286 | phase1 | completed | 2015-09-18 | 2021-11-04 | TG Therapeutics, Inc. | Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation |
FDA applications (0)
This company has no applications containing this asset.